Kano Therapeutics

Developer of circular single-stranded DNA for targeted gene-length DNA correction

placeCambridge, Massachusetts, United States calendar_todayFounded 2021 groups9 employees language kanotherapeutics.com

Social engagement

Social engagement: 4.1K social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

4 investors on record; lead investors include Engine Ventures, VSquared Ventures.

Investor typeCountShare
Venture capital4100%

Recent activity

5 May 2026
Event
ASGCT2026
5 Nov 2025
Recognition
4 Sep 2025
Partnership
Merck KGaA, Darmstadt, Germany
Coming soon